MARKET

APTO

APTO

Aptose
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.24
+0.32
+6.50%
After Hours: 5.26 +0.02 +0.38% 17:00 05/18 EDT
OPEN
4.950
PREV CLOSE
4.920
HIGH
5.33
LOW
4.930
VOLUME
814.64K
TURNOVER
--
52 WEEK HIGH
8.48
52 WEEK LOW
3.390
MARKET CAP
466.06M
P/E (TTM)
-7.3928
1D
5D
1M
3M
1Y
5Y
Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Zacks · 1d ago
Aptose to Present at Upcoming Investor Conferences
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor ...
GlobeNewswire · 6d ago
Caspase 3 Market Analysis (2021 - 2028)| By Key Players, Product Type, Application and Region By Ameco Research
pune, India, Fri, 07 May 2021 03:41:22 / Comserve Inc. / -- The global Caspase 3 market is segmented by company, region (country), by Type, and by...
Comserve · 05/07 07:42
RBC Capital Sticks to Its Buy Rating for Aptose Biosciences (APTO)
In a report issued on May 4, Gregory Renza from RBC Capital maintained a Buy rating on Aptose Biosciences (APTO), with a price target of $9.00. The
SmarterAnalyst · 05/07 01:49
Analysts Offer Insights on Healthcare Companies: Aptose Biosciences (APTO) and Arcutis Biotherapeutics (ARQT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptose Biosciences (APTO) and Arcutis Biotherapeutics
SmarterAnalyst · 05/04 23:56
10-Q: APTOSE BIOSCIENCES INC.
(EDGAR Online via COMTEX) -- Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form...
Edgar Online - (EDG = 10Q, 10K) · 05/04 21:18
Aptose Biosciences Q1 EPS $(0.18) Misses $(0.14) Estimate
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 20 percent decrease over losses of $(0.15) per share from
Benzinga · 05/04 20:14
Aptose Biosciences EPS misses by $0.01
Aptose Biosciences (APTO): Q1 GAAP EPS of -$0.18 misses by $0.01.Total cash and cash equivalents and investments as of March 31, 2021 were $112.1 million. Based on current operations, Aptose
Seekingalpha · 05/04 20:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APTO. Analyze the recent business situations of Aptose through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APTO stock price target is 11.00 with a high estimate of 13.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 87
Institutional Holdings: 50.81M
% Owned: 57.13%
Shares Outstanding: 88.94M
TypeInstitutionsShares
Increased
14
2.12M
New
12
1.82M
Decreased
16
3.79M
Sold Out
8
207.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/President/Chief Executive Officer/Director
William Rice
Chief Financial Officer/Chief Accounting Officer
Jotin Marango
Senior Vice President
Rafael Bejar
Vice President
Robert Killion
Vice President
George Melko
Lead Director/Independent Director
Denis Burger
Independent Director
Carol Ashe
Independent Director
Caroline Loewy
Independent Director
Erich Platzer
Independent Director
Mark Vincent
Independent Director
Warren Whitehead
No Data
About APTO
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Webull offers kinds of Aptose Biosciences Inc stock information, including NASDAQ:APTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APTO stock methods without spending real money on the virtual paper trading platform.